Diabetes

ENDO 2025: The publications reflect growing consensus that integration of endocrine screening into standard clinical workflows is essential for early risk detection and long-term disease prevention.

Richard Rosenfeld, MD, MPH, MBA, led the development of lifestyle medicine guidelines to treat or even reverse prediabetes and type 2 diabetes.

Lead author for the American College of Lifestyle Medicine's new clinical practice guideline discusses the broad endorsement for the recommendations across participating groups.

Jonathan Bonnet, MD, MPH, discusses common side effects of GLP-1 medications for obesity and how nutritional and behavioral strategies can help mitigate them.

Lifestyle medicine integrates a spectrum of therapeutic lifestyle interventions best delivered by specialists who are often available to create a "virtual" team.

Richard Rosenfeld, MD, MPH, MBA, lead author of new guidelines on sustained lifestyle change as central to treating, even reversing T2D, answers the question.

GLP-1 medications are transforming obesity medicine but strong evidence points to a need for integrating nutrition and lifestyle support for lasting weight loss and health benefits.

Richard Rosenfeld, MD, MPH, MBA, explains how clinical guidelines for diabetes remission from the American College of Lifestyle Medicine differ from and augment existing recommendations.

Caissa Troutman, MD, discusses how clinicians can tailor management plans to reduce risk of developing T2D in patients with obesity.

ADA 2025: Dapiglutide showed promising safety and weight loss results in a phase 1b trial, targeting obesity and inflammation with once-weekly dosing.

Obesity treatment evolves as GLP-1 medication use surges 587%, while bariatric surgery rates decline significantly. A new analysis parses the trends.

ADA 2025: Once-monthly dosing led to significant weight loss in adults with obesity, with or without type 2 diabetes, reported researchers.

ADA 2025: Mifepristone lowered HbA1c levels by about 1.5% over 24 weeks vs placebo among participants with hypercortisolism and inadequately controlled T2D.

ADA 2025: Orforglipron lowered HbA1C by an average of 1.3% to 1.6% across doses, with improvements seen as early as 4 weeks, in a phase 3 trial.

ADA 2025: Insulin efsitora proved noninferior to daily insulin glargine for reducing HbA1c, resulted in fewer episodes of hypoglycemia, and required fewer dose adjustments.

Advances in obesity pharmacotherapy will be the focus of numerous late-breaking science sessions at ADA 2025; snapshots of 5 studies follow.

The ADA unveils the association's first Standards of Care for Overweight and Obesity, with a chapter on weight stigma and bias one of the first released.

Your daily dose of the clinical news you may have missed.

For individuals with T2D, findings are more than numeric; a 5-mm Hg reduction in SBP reduces stroke risk by 14%, CV events by 6%, and heart failure by 8%, authors wrote.

The American College of Lifestyle Medicine recently published "that guideline," and lead author Richard Rosenfeld, MD, MPH, MBA, says the timing was right.

Your daily dose of the clinical news you may have missed.

These 14 recommendations from the American College of Lifestyle Medicine comprise the core of the first-ever guideline centered on lifestyle change as a first-line intervention.

High discontinuation rates as well as lower maintenance dosages of semaglutide and tirzepatide were among the independent predictors of lower real-world weight loss.

Novel guidelines include specific strategies that support the prescription, implementation, and monitoring of lifestyle changes to reach glycemic control and, possibly, disease remission.

Your daily dose of the clinical news you may have missed.